[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-who-grade-2-glioma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-who-grade-2-glioma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100505282","phase-2-testing-the-anti-cancer-drug-erdafitinib-for-brain-cancers-that-have-returned-or-progressed-following-treatment-100505282",false,"NCT05859334","Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment","A Phase 2 Study of Erdafitinib in Patients With Recurrent or Progressive IDH-Wild Type Glioma With an FGFR-TACC Gene Fusion","Inclusion Criteria:\n\n* Patient must be \\>= 18 years of age\n* Patient must have histologically confirmed IDH-WT gliomas (grade 2-4) as per World Health Organization (WHO) 2016 or 2021 classification\n* Tumor tissue should be positive for FGFR-TACC gene fusion as per any local next generation sequencing (NGS) (Clinical Laboratory Improvement Act \\[CLIA\\]-approved) assay described in background section\n* The disease should be recurrent or progressive glioma after initial anti-tumor treatment with at least 1 line of treatment including surgical resection, radiation therapy and\u002For chemotherapy\n* For patients with WHO grade 3 or 4 glioma and progressive disease \\\u003C 12 weeks after completion of chemoradiotherapy, progression can be defined by the following set of criteria:\n\n  * New enhancement outside of the radiation field (beyond the high-dose region or 80% isodose line)\n  * If there is unequivocal evidence of viable tumor on histopathologic sampling (e.g., solid tumor areas. i.e., \\> 70% tumor cell nuclei in areas), high or progressive increase in Ki-67 proliferation index compared with prior biopsy, or evidence for histologic progression or increased anaplasia in tumor)\n* For patients with WHO grade 3 or 4 glioma and progressive disease \\>= 12 weeks after completion of chemoradiotherapy, progression can be defined by the following set of criteria:\n\n  * New contrast-enhancing lesion outside of radiation field on decreasing, stable, or increasing doses of corticosteroids\n  * Increase by \\>= 25% in the sum of the products of perpendicular diameters between the first post-radiotherapy scan, or a subsequent scan with smaller tumor size, and the scan at 12 weeks or later on stable or increasing doses of corticosteroids\n  * For patients receiving antiangiogenic therapy, significant increase in T2\u002Ffluid attenuated inversion recovery (FLAIR) non-enhancing lesion may also be considered progressive disease. The increased T2\u002FFLAIR must have occurred with the patient on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy and not be a result of comorbid events (e.g., effects of radiation therapy, demyelination, ischemic injury, infection, seizures, postoperative changes, or other treatment effects)\n* For patients with WHO grade 2 glioma progression is defined by any one of the following:\n\n  * Development of new lesions or increase of enhancement (radiological evidence of malignant transformation)\n  * A 25% increase of the T2 or FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy, not attributable to radiation effect or to comorbid events\n* There must be measurable disease (enhancing or non-enhancing as per Response Assessment in Neuro-Oncology \\[RANO\\] or RANO-low-grade glioma \\[LGG\\] criteria), as evaluated on pre-treatment MRI\n* Patient understands the procedures and investigational nature of the study drug and agrees to comply with study requirements by providing written informed consent\n* Patient must have Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (or Karnofsky \\>= 60%)\n* Absolute neutrophil count \\>= 1000\u002FuL\n* Hemoglobin \\> 8 g\u002FdL (Patients are allowed to be transfused to this level)\n* Platelets \\>= 100 x 10\\^9\u002FL\n* Serum total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN), unless considered due to Gilbert's disease or disease involvement following approval by the medical monitor\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) =\\\u003C 3 x institutional ULN\n* Creatinine clearance \\> 30 mL\u002Fmin (patients with mild or moderate renal impairment) based on the Cockroft-Gault glomerular filtration rate (GFR) estimation\n* Patient must have normal serum phosphate level as per local laboratory parameters. (Medical management allowed)\n* Patient must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or chemotherapy treatment with temozolomide\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients should be New York Heart Association Functional Classification class 2B or better\n* The effects of erdafitinib on the developing human fetus are unknown. For this reason and because FGFR inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and one month after completion of erdafitinib administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and one month after completion of erdafitinib administration\n* Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants\n\nExclusion Criteria:\n\n* Patients who are receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to erdafitinib\n* Patients requiring any medications or substances that are moderate CYP2C9 inducers and strong CYP3A4 inducers are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment\u002Finformed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product\n* Patients with uncontrolled intercurrent illness\n* Pregnant women are excluded from this study because erdafitinib is an FGFR inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with erdafitinib, breastfeeding should be discontinued if the mother is treated with erdafitinib\n* Current central serous retinopathy (CSR) or retinal pigment epithelial detachment of any grade\n* Corrected QT interval (QTc) prolongation as confirmed by electrocardiography (ECG) at screening (Fridericia; QTc \\> 480 milliseconds)\n* Patients who have previously received FGFR inhibitors","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor cells to multiply. This may help keep tumor cells from growing and may kill them. Giving erdafitinib may help to slow the growth of, or to shrink, tumor cells in patients with recurrent or progressive IDH-wild type gliomas with FGFR-TACC gene fusion.",[26,27,28,29],"Recurrent Glioma","Recurrent WHO Grade 2 Glioma","Recurrent WHO Grade 3 Glioma","Recurrent WHO Grade 4 Glioma","RECRUITING","2026-06-16",{"date":33,"type":34},"2026-06-17","ACTUAL",{"date":36,"type":34},"2024-01-04",{"date":38,"type":20},"2026-10-23",{"name":40,"class":41},"National Cancer Institute (NCI)","NIH",27,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100547613","phase-1-triapine-in-combination-with-temozolomide-for-the-treatment-of-patients-with-recurrent-glioblastoma-100547613","NCT06410248","Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma","A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma","Inclusion Criteria:\n\n* Patients must have histologically confirmed World Health Organization (WHO) grade 2-4 glioma, isocitrate dehydrogenase (IDH) wild type (WT) (by immunohistochemistry \\[IHC\\] R132H negative \\[neg\\] or sequencing). Astrocytoma with molecular features of glioblastoma (GBM). Confirmed diagnosis via molecular testing\n* Patients must have an established diagnosis of recurrent glioblastoma and:\n\n  * Group 1 and 2: recurrent glioblastoma\n  * Group 3: Surgically amenable recurrent glioblastoma\n* Patients must have stable or decreasing dose of corticosteroids equivalent to ≤ 6 mg dexamethasone, for ≥ 7 days prior to registration\n* Patients with disease that has progressed after a standard or investigational first-line therapy (e.g. radiotherapy \\[RT\\], RT plus temozolomide) with or without tumor treating fields therapy (TTFields)\n\n  * Note: Patients who have received fractionated first-line radiation therapy and no prior chemotherapy (e.g. as common practice for MGMT unmethylated tumors), or who have participated in an investigational protocol substituting TMZ for a novel agent are eligible\n* Patients must be able to undergo contrast-enhanced magnetic resonance imaging (MRI)\n* Patients must be age ≥ 18 years\n* Patients must exhibit a Karnofsky performance status ≥ 70\n* Leukocytes (white blood cells \\[WBC\\]) ≥ 3,000\u002FmcL\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FmcL\n* Hemoglobin (Hgb) ≥ 8 g\u002FdL (transfusion may be used for eligibility outside of 7 days)\n* Platelets (PLT) ≥ 100,000\u002FmcL (transfusion or growth factor may be used for eligibility outside of 7 days)\n* Total bilirubin ≤ 2 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) ≤ 3 x institutional ULN\n* Creatinine ≤ 1.5 x institutional ULN\n* International normalized ratio (INR) ≤ 1.5 x ULN\n* Prothrombin time (PT)\u002Fpartial thromboplastin time (PTT) ≤ 1.5 x ULN\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better\n* Patients of child-bearing potential (POCBP) must agree to use two forms of adequate contraception (hormonal or barrier method of birth control, abstinence) from time of informed consent and for the duration of study participation. Patients who can impregnate their partners must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) from time of informed consent and for the duration of study participation\n\n  * Should a patient become pregnant or suspect they are pregnant while they or their partner is participating in this study, they should inform their treating physician immediately.\n  * Note: At the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence \\[e.g., calendar, ovulation, symptothermal, postovulation methods\\] and withdrawal are not acceptable methods of contraception.)\n  * Note: A POCBP is any person with an egg-producing reproductive tract (regardless of gender, sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n    * Has not undergone a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy\n    * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months) (in patients \\> 45 years of age in the absence of other biological or physiological causes)\n\n      * Potential POCBP who may be menopausal and are \\\u003C 55 years of age must have a serum follicle-stimulating hormone (FSH) level \\> 40 mIU\u002FmL to confirm menopause\n      * Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff\n* Patient must be willing and able to comply with the protocol for the duration of the study and provide written, signed, and dated informed consent prior to study registration.\n\n  * NOTE: No study-specific screening procedures may be performed until written consent has been obtained\n* Patients must have the ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients who have a prior or concurrent malignancy that may interfere with study treatment or safety\n\n  * NOTE: Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible, per principal investigator (PI) discretion\n* Patients who are receiving any other investigational agents.\n\n  * Exceptions: COVID-19 vaccine and treatment is allowed, per PI's discretion\n* Patient's interval since last cytotoxic therapy ≥ 1 cycle or ≥ 2 biological half-lives, i.e.\n\n  * ≥ 28 days since start of last cycle of temozolomide (cycle length-28 days)\n  * ≥ 42 days since start of last cycle of lomustine or other nitrosourea (cycle length-42 days)\n  * ≥ 21 days since start of last cycle of a small molecule targeted agent (cycle length-21 days)\n  * ≥ 42 days from last bevacizumab infusion (cycle length-42 days)\n* Patients who have a history of allergic reactions attributed to compounds of similar chemical composition to temozolomide or triapine\n* Patients with spinal cord and diffuse leptomeningeal dissemination\n* Patients with a history of G6PD deficiency or other congenital or autoimmune hemolytic disorders. All participants will be screened for G6PD levels prior to registration\n* Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following:\n\n  * Have uncontrolled epilepsy\n  * Have an uncontrolled intercurrent illness\n  * Are pregnant or nursing\n  * Concurrent malignancy (outside of glioblastoma) that requires tumor directed treatment\n  * Known concurrent shingles, herpes, cytomegalovirus (CMV) infection\n  * Known concurrent opportunistic fungal infection\n  * Known immunodeficiency that could lead to opportunistic infections\n  * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n  * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints\n* Patients who are pregnant or nursing. Pregnant patients are excluded from this study because temozolomide is an alkylating agent with potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temozolomide, breastfeeding should be discontinued if the mother is treated with temozolomide\n* Patients who are unable to swallow oral medication or have problems\u002Fdiseases that affect absorption or oral medication\n* Patients with a known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and\u002For hepatitis C virus (HCV). If patient does not have a known history testing will not be conducted\n\n  * Note: Temozolomide is an immunosuppressive agent. Patients with a known history of HIV, HBV, and HCV, and unexplained opportunistic infections are not eligible due to safety reasons",{"count":19,"type":20},[52],"PHASE1","This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and\u002For effective in treating patients with recurrent glioblastoma.",[55,27,28,29],"Recurrent Glioblastoma, IDH-Wildtype","2026-04-29",{"date":58,"type":34},"2026-05-01",{"date":60,"type":34},"2024-07-23",{"date":62,"type":20},"2030-05-12",{"name":64,"class":65},"Northwestern University","OTHER",1]